Chimeric antigen receptor T cell therapy
AssigneeKite Pharma, Inc.
InventorsAdrian Bot, John Rossi
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy.
Claims9
A method for treating relapsed or refractory mantle cell lymphoma (MCL) in a subject in need thereof that has a Ki-67 tumor proliferation index ≥50% or presence of a TP53 mutation, comprising administering to the subject a therapeutically effective amount of a composition which comprises autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) wherein the T cells comprise CD4+ and CD8+ CAR T cells that are prepared from peripheral blood mononuclear cells (PBMCs) by positive enrichment and partial or complete depletion of circulating cancer cells and wherein the anti-CD19 CAR comprises an anti-CD19 single-chain variable fragment (scFv) comprising the heavy chain and light chain variable regions of FMC63, a CD28 intracellular signaling region, and a CD3-zeta signaling domain.
Dependencies are inferred from the claim text.